Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881542 | 0.77 | KDM5B (0.39) | KDM5B | |
| SCHEMBL9773308 | 0.70 | DAO (0.44) | KDM5BTDP2GRIN1GRIN2B | |
| SCHEMBL21547828 | 0.67 | GAA (0.41) | — | |
| SCHEMBL10989579 | 0.66 | KDM5B (0.40) | KDM5BTDP2 | |
| SCHEMBL10364313 | 0.65 | DAO (0.31) | TDP2GRIN1GRIN2B | |
| SCHEMBL21366194 | 0.63 | COMT (0.36) | — | |
| SCHEMBL9844407 | 0.63 | TDP2 (0.35) | KDM5BTDP2GRIN1GRIN2B | |
| SCHEMBL11840289 | 0.63 | GRIN1 (0.36) | KDM5BTDP2GRIN1GRIN2B | |
| SCHEMBL10355632 | 0.61 | MAPK14 (0.33) | KDM5BGRIN1GRIN2B | |
| SCHEMBL15748053 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901866-A | Metal coated substrate | 阿梅迪洛金属涂层有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-8338460-B2 | 3-({4-[2-(dimethylamino)ethoxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide; glucokinase activator; antidiabetic, obesity | MSD K. K. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2077266-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | MSD KK (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20100261699-A1 | N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| EP-2236507-A1 | N-PYRAZOLE-2-PYRIDINECARBOXAMIDE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-10-06 | — | — | EP | disclosed |
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | GCKR, GCK, GPR119 | KDM5B 1157/4885TDP2 3792/4885GRIN1 231/4885 |
| US-20100261699-A1 | N-PYRAZOLE-2-PYRIDINE CARBOXAMIDE DERIVATIVE | GCKR, GPR119, GCK | KDM5B 1701/4885TDP2 4126/4885GRIN1 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.